发明名称 Axitinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable
摘要 Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
申请公布号 LU92154(I2) 申请公布日期 2013.04.22
申请号 LU20130092154C 申请日期 2013.02.20
申请人 AGOURON PHARMACEUTICALS, INC. 发明人
分类号 A61K31/416;A61K31/4178;A61K31/4184;A61K31/4188;A61K31/4196;A61K31/4245;A61K31/427;A61K31/437;A61K31/4439;A61K31/444;A61K31/454;A61K31/4709;A61K31/496;A61K31/5377;A61P3/10;A61P9/10;A61P17/06;A61P19/02;A61P27/02;A61P27/06;A61P29/00;A61P35/00;A61P43/00;C07D209/18;C07D231/00;C07D231/56;C07D401/04;C07D401/06;C07D401/12;C07D401/14;C07D403/04;C07D403/12;C07D403/14;C07D405/04;C07D405/06;C07D405/14;C07D409/06;C07D409/12;C07D409/14;C07D413/12;C07D413/14;C07D417/06;C07D417/12;C07D417/14;C07D471/04;C07D491/04;C07D491/056 主分类号 A61K31/416
代理机构 代理人
主权项
地址